|
全国免费电话：400-668-6834 -- 仅限中国地区 -- |
在线订购：QQ: 4006686834 电话订购：021-68591985 邮件订购：info@selleck.cn 我们也提供销售人员上门服务 |
技术支持电话：400-168-6834 我们将于一个工作日与您联系 |
Tiragolumab (anti-TIGIT)
目录号：A2028 批次号: A202801
Tiragolumab (anti-TIGIT) (RG6058, MTIG7192A) 是一种人源化 IgG1/kappa 单克隆抗体，可与 TIGIT 结合以防止其与其配体 PVR (CD155) 相互作用。
抗体信息
| CAS号 | 1918185-84-8 |
|---|---|
| 推荐同型对照 | Human IgG1, κ |
| 来源 | CHO cells |
| 储存条件 (自收到货起) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles. |
| 除菌 | 0.2 μM filtered |
| 纯度 | 99.33% |
| 蛋白浓度 | 4.72 mg/ml |
| 内毒素 | <1 EU/mg |
Tiragolumab (anti-TIGIT)在文献中得到引用
| Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer [ Cancer Cell, 2024, 42(12):2045-2063.e10] | PubMed: 39658541 |
| Inhibition of Cbl-b restores effector functions of human intratumoral NK cells [ J Immunother Cancer, 2024, 12(11)e009860] | PubMed: 39551607 |
| The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling [ Cell Commun Signal, 2024, 22(1):35] | PubMed: 38216949 |
| Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancer [ bioRxiv, 2024, 2024.03.19.585657] | PubMed: 38562799 |
| Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies [ J Immunother Cancer, 2023, 11(12)e007502] | PubMed: 38081778 |
禁止用于人体及治疗！